Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults

Review evidence from the latest clinical trials of tralokinumab, a new systemic interleukin-13 inhibitor for moderate-to-severe atopic dermatitis.Skin Therapy Letter
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news